Jiaochen Biopharmaceutical Technology

Jiaochen Biopharmaceutical Technology (also known as General Regeneratives and Usynova) is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on developing innovative therapies for oncology and autoimmune diseases. The company utilizes its proprietary Prometheus Technology for biologics and a specialized small molecule discovery platform to target challenging disease mechanisms. Its lead program, UA007 (formerly GR007), is a recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) currently in Phase 2 clinical trials for the prevention of chemotherapy-induced toxicities and the treatment of acute gout. Jiaochen's pipeline also includes UA021, a TYK2 inhibitor in Phase 2 for psoriasis, and UA022, a KRAS G12D inhibitor licensed to AstraZeneca in a significant global partnership. The company is backed by prominent investors such as Morningside Group and Shenzhen Share Capital.